Paulo Gustavo kotze

List of Publications by Citations

Source: https://exaly.com/author-pdf/3378967/paulo-gustavo-kotze-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

174 2,290 21 43 g-index

193 3,370 3.8 5.17 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
174	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohnl</i> s and Colitis, 2019 , 13, 144-164	1.5	427
173	European evidence based consensus on surgery for ulcerative colitis. <i>Journal of Crohnl</i> s and Colitis, 2015 , 9, 4-25	1.5	209
172	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. <i>Journal of Crohnl</i> s and Colitis, 2019 , 13, 273-284	1.5	132
171	Crohn's disease. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 22	51.1	131
170	Modern management of perianal fistulas in Crohn's disease: future directions. <i>Gut</i> , 2018 , 67, 1181-1194	1 19.2	79
169	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus. <i>Journal of Crohnh</i> and Colitis, 2018 , 12, 408-418	1.5	66
168	Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 304-312	6.9	61
167	Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. <i>United European Gastroenterology Journal</i> , 2016 , 4, 784-793	5.3	52
166	Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 456-464	4	46
165	Mesenchymal Stem Cells for Perianal Crohn's Disease. <i>Cells</i> , 2019 , 8,	7.9	41
164	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs. <i>Journal of Crohnh</i> and Colitis, 2016 , 10, 758-65	1.5	40
163	Surgery in ulcerative colitis: When? How?. <i>Baillierels Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 71-78	2.5	37
162	Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. <i>Gastrointestinal Endoscopy</i> , 2019 , 89, 215-237	5.2	37
161	Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 626-637	6.1	34
160	Evolving Role of IBD Surgery. <i>Journal of Crohnl</i> s and Colitis, 2018 , 12, 1005-1007	1.5	33
159	Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 393-405	18.8	32
158	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. <i>The Lancet Gastroenterology and Hepatology</i> . 2019 . 4. 287-295	18.8	29

157	Clinical utility of ustekinumab in Crohn's disease. Journal of Inflammation Research, 2018, 11, 35-47	4.8	23
156	Perianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn's disease: a Brazilian multicenter observational study. <i>Arquivos De Gastroenterologia</i> , 2014 , 51, 284-9	1.3	22
155	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1366-1376.e2	6.9	22
154	Perioperative Dietary Therapy in Inflammatory Bowel Disease. <i>Journal of Crohnl</i> s and Colitis, 2020 , 14, 431-444	1.5	22
153	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 115-123	0.5	21
152	Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database. <i>Journal of Crohnl</i> s and Colitis, 2015, 9, 541-7	1.5	19
151	Antibodies anti-Saccharomyces cerevisiae (ASCA) do not differentiate Crohn's disease from celiac disease. <i>Arquivos De Gastroenterologia</i> , 2010 , 47, 242-5	1.3	19
150	Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 702-710	24.2	19
149	Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel DiseaseFocus on clinical evaluation of monoclonal antibodies and fusion	13.6	18
148	proteins used in the treatment of autoimmune diseases. <i>Autoimmunity Reviews</i> , 2015 , 14, 769-73 Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease. <i>Intestinal Research</i> , 2017 , 15, 352-357	4.1	18
147	The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil. <i>Current Opinion in Gastroenterology</i> , 2019 , 35, 259-264	3	18
146	Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn's disease: a multicentre observational study. <i>Colorectal Disease</i> , 2017 , 19, O39-O45	2.1	16
145	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. <i>Revista De Gastroenterolog</i> De M\(\textit{Bico}, \textit{2017}, 82, 46-84	0.7	15
144	Fluorescence angiography during transanal trans-stomal proctectomy and ileal pouch anal anastomosis: a video vignette. <i>Colorectal Disease</i> , 2017 , 20, 262	2.1	15
143	The impact of biologics in surgical outcomes in ulcerative colitis. <i>Bailliereh Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 79-87	2.5	15
142	Adalimumab and postoperative complications of elective intestinal resections in Crohn's disease: a propensity score case-matched study. <i>Colorectal Disease</i> , 2017 , 20, 211	2.1	14
141	Fistula-associated anal carcinoma in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 917-925	4.2	14
140	Impact of Preoperative Nutritional Status on the Incidence Rate of Surgical Complications in Patients With Inflammatory Bowel Disease With Vs Without Preoperative Biologic Therapy: A Case-Control Study. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00050	4.2	12

139	Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease. <i>Drugs of Today</i> , 2019 , 55, 95-105	2.5	12
138	The impact of surgical therapies for inflammatory bowel disease on female fertility. <i>The Cochrane Library</i> , 2019 , 7, CD012711	5.2	12
137	Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2374-23	378.e2	11
136	International Organization for the Study of IBD Recommendations for Surgery in Patients With IBD During the Coronavirus Disease 2019 Pandemic. <i>Diseases of the Colon and Rectum</i> , 2020 , 63, 870-873	3.1	11
135	Is there any relation between gastric bypass for morbid obesity and the development of Crohn's disease?. <i>Journal of Crohnl</i> s and Colitis, 2014 , 8, 712-3	1.5	11
134	FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. <i>Arquivos De Gastroenterologia</i> , 2015 , 52, 50-4	1.3	11
133	Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review <i>Gastroenterology</i> , 2022 ,	13.3	11
132	Motor neuropathy with multiple conduction blocks associated with TNF-alpha antagonist. <i>Arquivos De Neuro-Psiquiatria</i> , 2010 , 68, 452-4	1.6	11
131	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. <i>Intestinal Research</i> , 2018 , 16, 522-	5 2 5	11
130	Ileal pouch-anal anastomosis with fluorescence angiography: a case-matched study. <i>Colorectal Disease</i> , 2019 , 21, 827-832	2.1	9
129	Sarcoidosis during therapy with adalimumab in a Crohn's disease patient: a paradoxical effect. Journal of Crohnls and Colitis, 2013, 7, e599-600	1.5	9
128	Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. <i>Intestinal Research</i> , 2017 , 15, 160-165	4.1	9
127	Review of the epidemiology and burden of ulcerative colitis in Latin America. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820931739	4.7	9
126	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 482-497	18.8	9
125	Fistulizing Crohn's disease. Current Problems in Surgery, 2020 , 57, 100808	2.8	8
124	Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818783614	4.7	8
123	Long Time from Diagnosis to Surgery May Increase Postoperative Complication Rates in Elective CD Intestinal Resections: An Observational Study. <i>Gastroenterology Research and Practice</i> , 2018 , 2018, 4703	3 2 81	8
122	VISCERAL FAT IS INCREASED IN INDIVIDUALS WITH CROHN'S DISEASE: A COMPARATIVE ANALYSIS WITH HEALTHY CONTROLS. <i>Arquivos De Gastroenterologia</i> , 2018 , 55, 142-147	1.3	8

(2020-2011)

121	Biological therapy does not increase post operative complications after major abdominal surgery in crohn disease brazilian patients. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, S43	4.5	8	
120	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 826-849	18.8	8	
119	Postoperative topical analgesia of hemorrhoidectomy with policresulen and cinchocaine: a prospective and controlled study. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2014 , 41, 92-8	0.5	7	
118	Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study. <i>Arquivos De Gastroenterologia</i> , 2014 , 51, 39-45	1.3	7	
117	BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES. <i>Arquivos De Gastroenterologia</i> , 2019 , 56, 318-322	1.3	7	
116	Effects of anti-TNF-In experimental diversion colitis. <i>Acta Cirurgica Brasileira</i> , 2019 , 34, e201901004	1.6	7	
115	Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery. <i>Current Drug Targets</i> , 2019 , 20, 1339-1348	3	7	
114	Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820931738	4.7	7	
113	Disease duration did not influence the rates of loss of efficacy of the anti-TNF therapy in Latin American Crohn disease patients. <i>Digestion</i> , 2015 , 91, 158-63	3.6	6	
112	T300A genetic polymorphism: a susceptibility factor for Crohn's disease?. <i>Arquivos De Gastroenterologia</i> , 2014 , 51, 97-101	1.3	6	
111	Epidemiological profile of 175 patients with Crohn's disease submitted to biological therapy. Journal of Coloproctology, 2012 , 32, 395-401	0.5	6	
110	Postoperative Approach for Crohn's Disease: The Right Therapy to the Right Patient. <i>Current Drug Targets</i> , 2018 , 19, 729-739	3	6	
109	Biological Therapy for the Prevention and Treatment of Postoperative Endoscopic Recurrence in Crohn's Disease: Time for Acceptance?. <i>Intestinal Research</i> , 2013 , 11, 256	4.1	6	
108	Conventional Versus Biological Therapy for Prevention of Postoperative Endoscopic Recurrence in Patients With Crohn's Disease: an International, Multicenter, and Observational Study. <i>Intestinal Research</i> , 2015 , 13, 259-65	4.1	6	
107	Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease. <i>Intestinal Research</i> , 2018 , 16, 62-68	4.1	6	
106	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2021 , 9, 451-	-4ēø	6	
105	Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn's Disease and Individuals with Obesity Before and After Bariatric Surgery. <i>Obesity Surgery</i> , 2018 , 28, 378-388	3.7	6	
104	Up-to-date surgery for ulcerative colitis in the era of biologics. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 391-398	5.4	5	

103	The impact of preoperative anti-TNF in surgical and infectious complications of abdominal procedures for Crohn's disease: controversy still persists. <i>American Journal of Gastroenterology</i> , 2014 , 109, 139	0.7	5
102	Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn's disease?. <i>Journal of Crohnl</i> s and Colitis, 2013 , 7, e712	1.5	5
101	Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists. <i>Arquivos De Gastroenterologia</i> , 2015 , 52, 76-80	1.3	5
100	Anlise de custo-minimizab entre o Infliximabe (IFX) e o Adalimumabe (ADA) no tratamento da doena de Crohn (DC). <i>Revista Brasileira De Coloproctologia</i> , 2009 , 29, 158-168		5
99	Burrill Bernard Crohn (1884-1983): the man behind the disease. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2013 , 26, 253-5	1.7	5
98	Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?. <i>Current Drug Targets</i> , 2019 , 20, 1369-1372	3	5
97	Hypoalbuminemia as a risk factor for thromboembolic events in inflammatory bowel disease inpatients. <i>Intestinal Research</i> , 2019 , 17, 63-69	4.1	5
96	Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?. <i>Journal of Crohnl</i> s and Colitis, 2017 , 11, 643	1.5	5
95	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 857-873	24.2	5
94	Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. <i>Colorectal Disease</i> , 2019 , 21, 1279-1287	2.1	4
93	SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT. <i>Arquivos De Gastroenterologia</i> , 2018 , 55, 192-197	1.3	4
92	Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. <i>Journal of Medical Economics</i> , 2016 , 19, 118	7 -211 99	4
91	Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211005708	4.7	4
90	Postoperative mortality in inflammatory bowel disease patients. <i>Journal of Coloproctology</i> , 2017 , 37, 116-122	0.5	3
89	Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives. <i>Crohnl</i> s & Colitis 360, 2019, 1,	1.4	3
88	Complications after intestinal resection in Crohn's disease: laparoscopic versus conventional approach. <i>Journal of Coloproctology</i> , 2013 , 33, 139-144	0.5	3
87	ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY. <i>Arquivos De Gastroenterologia</i> , 2017 , 54, 321-327	1.3	3
86	Effect of anti-TNF-Ibn peritoneal endometrial implants of rats. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2011 , 38, 266-73	0.5	3

(2013-2019)

85	Cell-based Therapy for Perianal Fistulising Crohn's Disease. <i>Current Pharmaceutical Design</i> , 2019 , 25, 41-46	3.3	3	
84	VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY. <i>Arquivos De Gastroenterologia</i> , 2019 , 56, 312-317	1.3	3	
83	Robotic Surgery in Inflammatory Bowel Disease. Current Drug Targets, 2021, 22, 112-116	3	3	
82	Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series. <i>Journal of Coloproctology</i> , 2011 , 31, 233-240	0.5	3	
81	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021 , 20, 102849	13.6	3	
80	Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3	
79	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. <i>Revista De Gastroenterolog De M\(\textit{Z}\) ico (English Edition)</i> , 2017 , 82, 46-84	0.2	2	
78	Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). <i>Revista De Gastroenterolog</i> a De Mico, 2017 , 82, 134-155	0.7	2	
77	Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review. <i>Journal of Coloproctology</i> , 2015 , 35, 128-136	0.5	2	
76	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1208-1209	6.1	2	
75	SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB. <i>Arquivos De Gastroenterologia</i> , 2017 , 54, 328-332	1.3	2	
74	TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES. <i>Arquivos De Gastroenterologia</i> , 2018 , 55, 198-200	1.3	2	
73	P511 Does the location of an IBD centre impact the rates of early postoperative endoscopic recurrence after ileocecal resection in Crohn's disease? Results from the MULTIPER database. <i>Journal of Crohnl</i> s and Colitis, 2014 , 8, S281	1.5	2	
72	Human fibrinogen and thrombin patch for extraluminal protection of intestinal anastomosis. <i>Journal of Coloproctology</i> , 2013 , 33, 174-178	0.5	2	
71	Infliximab versus azathioprine to prevent postoperative recurrence in Crohn's disease: are all controversial issues defined?. <i>Journal of Crohnh</i> and Colitis, 2013 , 7, e698	1.5	2	
70	Double single-port transanal pouch surgery: a novel technique for rectal excision and ileo-anal pouch anastomosis for ulcerative colitis. <i>Journal of Coloproctology</i> , 2017 , 37, 328-331	0.5	2	
69	Adalimumab for perianal fistulizing Crohn's disease: real-world data adds important information for clinical practice. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49, 174-5	3	2	
68	Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa mesalazine 2 g sachet. <i>Arquivos De Gastroenterologia</i> , 2013 , 50, 297-303	1.3	2	

67	A broad panel of autoantibodies in patients with celiac disease and Crohn's disease. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 309-10	3	2
66	Obesity and Crohn's disease: what comes first, the egg or the chicken?. <i>Arquivos De Gastroenterologia</i> , 2017 , 54, 268	1.3	2
65	ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL. <i>Arquivos De Gastroenterologia</i> , 2016 , 53, 60-1	1.3	2
64	Influficia da tĉnica de anestesia no tempo de ocupa ß de sala cirfigica nas operafis anorretais. <i>Revista Brasileira De Coloproctologia</i> , 2008 , 28, 227-233		2
63	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 ,	18.8	2
62	Sucralfate enemas reduce the oxidative tissue damage and preserves the contents of E-cadherin and ?-catenin in colonic mucosa without fecal stream. <i>Acta Cirurgica Brasileira</i> , 2021 , 36, e361007	1.6	2
61	Endoscopic postoperative recurrence rates in Crohn's disease in Korea: the beginning of a new approach?. <i>Intestinal Research</i> , 2014 , 12, 258-9	4.1	2
60	Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 189-190	6.1	2
59	Perioperative management of ileocecal Crohn's disease in the current era. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 843-855	4.2	2
58	Adjunctive Hyperbaric Oxygen Therapy in Refractory Crohn's Disease: An Observational Study. <i>Gastroenterology Research and Practice</i> , 2021 , 2021, 6628142	2	2
57	Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?. <i>Inflammatory Intestinal Diseases</i> , 2022 , 7, 13-20	2.5	2
56	The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 429-440	6.1	2
55	COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 3033-3040	4	2
54	Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. <i>Journal of Crohnh</i> and Colitis, 2016 , 10, 626-7	1.5	2
53	Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic. <i>Gastroenterology</i> , 2021 , 160, 472-473	13.3	2
52	Surgery for Inflammatory Bowel Disease Has Unclear Impact on Female Fertility: A Cochrane Collaboration Systematic Review. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, 115-	12:4	2
51	Management of Isolated Anal Strictures in Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , 2020 , 63, 1639-1647	3.1	1
50	Reduction of surgical rates in inflammatory bowel diseases biologic era: Similarities between Spain and Latin America. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1453	4	1

49	The old versus the new: which do you keep in postoperative Crohn's disease?. <i>Intestinal Research</i> , 2018 , 16, 319-320	4.1	1
48	P388 Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme. <i>Journal of Crohnl</i> s and Colitis, 2019 , 13, S301-S302	1.5	1
47	Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 969-970	6.1	1
46	Comparative analysis of adverse events between infliximab and adalimumab in Crohn's disease management: a Brazilian single-centre experience. <i>Journal of Coloproctology</i> , 2013 , 33, 033-038	0.5	1
45	Postoperative complication rates between Crohn's disease and Colorectal cancer patients after ileocolic resections: a comparative study. <i>Journal of Coloproctology</i> , 2017 , 37, 290-294	0.5	1
44	Appropriateness of colonoscopy indication for colorectal neoplasm detection in patients under 50 years old with hematochezia. <i>Journal of Coloproctology</i> , 2012 , 32, 40-49	0.5	1
43	Anlise das complicales tardias em operales anorretais: experificia de um servilo de referlicia em coloproctologia. <i>Revista Brasileira De Coloproctologia</i> , 2010 , 30, 305-317		1
42	MANAGEMENT OF ILEOCECAL CROHN'S DISEASE DURING SURGICAL TREATMENT FOR ACUTE APPENDICITIS: A SYSTEMATIC REVIEW <i>Arquivos De Gastroenterologia</i> , 2021 , 58, 560-565	1.3	1
41	Reinduß da remissß clßica com adalimumabe apß interrupß do tratamento: uma alternativa no manejo da doenß de Crohn. <i>Revista Brasileira De Coloproctologia</i> , 2010 , 30, 135-140		1
40	Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
39	Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. <i>Current Drug Targets</i> , 2019 , 20, 1327-1338	3	1
38	Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?. <i>Clinics</i> , 2019 , 74, e1424	2.3	1
37	Training on Minimally Invasive Colorectal Surgery during Surgical Residency: Integrating Surgical Education and Advanced Techniques. <i>Clinics in Colon and Rectal Surgery</i> , 2021 , 34, 194-200	2.3	1
36	Preoperative Anti-TNF Agents and Morbidity After Ileocolonic Resections in Crohn's Disease: Are Biologics the Only Ones to Blame?. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 1352-1353	3.3	1
35	CORRELATION BETWEEN TROUGH LEVELS OF INFLIXIMAB AND POSTOPERATIVE ENDOSCOPIC RECURRENCE IN CROHN'S DISEASE PATIENTS SUBMITTED TO ILEOCOLONIC RESECTIONS: A SYSTEMATIC REVIEW. <i>Arquivos De Gastroenterologia</i> , 2021 , 58, 107-113	1.3	1
34	Practical insights into stomas in inflammatory bowel disease: what every healthcare provider needs to know. <i>Current Opinion in Gastroenterology</i> , 2021 , 37, 320-327	3	1
33	Inflammatory bowel disease epidemiology data from a prospective registry in Cfdoba, Argentina: Raising the bar for future studies in Latin America. <i>Digestive and Liver Disease</i> , 2021 , 53, 1212-1213	3.3	1
32	Sacrococcygeal hernia: a challenge for the coloproctologist. <i>Journal of Coloproctology</i> , 2012 , 32, 416-42	- 2 1 0.5	O

31	Training for Minimally Invasive Surgery for IBD: A Current Need. <i>Clinics in Colon and Rectal Surgery</i> , 2021 , 34, 172-180	2.3	О
30	Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey. <i>World Journal of Gastroenterology</i> , 2021 , 27, 1226-1239	5.6	O
29	DOP41 Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study. <i>Journal of Crohnl</i> s and Colitis, 2021 , 15, SO	79 ¹ 5081	0 ^O
28	Perioperative Nutritional Optimization in Inflammatory Bowel Diseases: When and How?. <i>Journal of Coloproctology</i> , 2021 , 41, 295-300	0.5	О
27	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021 , 53, 1571-1579	3.3	O
26	Importance of Nutrition and Hypoalbuminaemia in Postoperative Morbidity in Crohn's Disease: Thinking Outside of the Box on Biologics as Single Risk Factors. <i>Journal of Crohnl</i> s and Colitis, 2021 , 15, 1401-1402	1.5	O
25	Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn's disease: a narrative review. <i>Intestinal Research</i> , 2021 , 19, 255-264	4.1	О
24	Optimal strategies to prevent recrudescent Crohn's disease after resection. <i>Seminars in Colon and Rectal Surgery</i> , 2020 , 31, 100746	0.3	
23	Staging surgery for ulcerative colitis: more than meets the eye. <i>International Journal of Colorectal Disease</i> , 2018 , 33, 109-110	3	
22	SURGICAL STRATEGIES IN MULTIDISCIPLINARY MANAGEMENT OF CROHN'S DISEASE. <i>Revista Midica Cl</i> ica Las Condes, 2019 , 30, 349-356	0.2	
21	Taylored prevention of postoperative endoscopic recurrence in Crohn's disease: new data for an old problem. <i>Journal of Coloproctology</i> , 2014 , 34, 065-066	0.5	
20	Risk factors for postoperative endoscopic recurrence in Crohn's disease: a Brazilian observational study. <i>Journal of Coloproctology</i> , 2014 , 34, 141-147	0.5	
19	P-128 Risk Factors for Postoperative Endoscopic Recurrence in Crohn's DiseaseA Brazilian Multicenter Observational Study. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, S74-S75	4.5	
18	P-129 Self-injections and Adherence with Adalimumab Therapy in Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, S75	4.5	
17	Anlise de custos entre a raquianestesia e a anestesia venosa com propofol associada ao bloqueio perianal local em operalis anorretais. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2009 , 22, 137-142	1.7	
16	P-111 Combined Therapy With Surgery and Anti-TNF Therapy for Perianal Crohn's Disease: Seton Withdrawal Timing Data From a Brazilian Case Series. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S59	4.5	
15	P563 Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme. <i>Journal of Crohnl</i> s and Colitis, 2022, 16, i506-i507	1.5	
14	The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases <i>Clinics in Colon and Rectal Surgery</i> , 2022 , 35, 3-4	2.3	

13	PREVALENCE OF SELF-MEDICATION FOR DYSPEPTIC SYMPTOMS IN PRIMARY CARE: A BRAZILIAN SURVEY. <i>Arquivos De Gastroenterologia</i> , 2021 , 58, 364-369	1.3
12	Can Surgery for Inflammatory Bowel Disease be Personalized?. Current Drug Targets, 2018, 19, 798-804	3
11	INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE. <i>Arquivos De Gastroenterologia</i> , 2020 , 57, 507-510	1.3
10	THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era. <i>Arquivos De Gastroenterologia</i> , 2016 , 53, 3-4	1.3
9	Microscopic Inflammation at Ileocaecal Resection Margins in Crohn's Disease: Prevent Recurrence or Treat Residual Disease?. <i>Journal of Crohnl</i> s and Colitis, 2020 , 14, 872-873	1.5
8	Advances in Inflammatory Bowel Diseases 2020 Virtual: Key Take-Home Points. <i>Diseases of the Colon and Rectum</i> , 2021 , 64, 774-776	3.1
7	DOP61 Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study.	1.5
6	P644 Hospitalization and abdominal surgery rates in CD according to drug-dispensing: a temporal trend analysis from the Brazilian public healthcare national system. <i>Journal of Crohnl</i> s and Colitis, 2021 , 15, S576-S577	1.5
5	P591 Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB). <i>Journal of Crohnl</i> s and Colitis, 2021 , 15, S540-S541	1.5
4	Patients' perceptions of surgery for inflammatory bowel disease. <i>Colorectal Disease</i> , 2021 , 23, 2690-269	8.1
3	P436 Ileal pouch-anal anastomosis with fluorescence angiography: Initial experience and potential application. <i>Journal of Crohnl</i> s and Colitis, 2018 , 12, S325-S325	1.5
2	Letter: can a specific surgical approach reduce post-operative recurrence in Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1030-1031	6.1
1	Endoscopic evaluation after surgery in inflammatory bowel disease - Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 691-692	18.8